Please use this identifier to cite or link to this item: http://cuir.car.chula.ac.th/handle/123456789/61734
Title: Long-term effectiveness of omalizumab treatment in Thai severe asthmatic patients: a real-life experience
Authors: Theerasuk Kawamatawong
Orapan Poachanukoon
Chalermporn Boonsiri
Atik Saengasapaviriya
Chanchai Sittipunt
Hiroshi Chantaphakul
Kittipong Maneechotesuwan
Pintip Ngamchanyaporn
Kunchit Piyavechviratana
Praparn Yongjaiyut
Apichart Khanisap
Siwasak Juthong
Warangkana Rithirak
Prapaporn Pornsuriyasak
Chaicharn Pothirat
Watchara Boonsawat
Email: No information provided
No information provided
No information provided
No information provided
Chanchai.Si@Chula.ac.th
Hiroshi.C@Chula.ac.th
No information provided
No information provided
No information provided
No information provided
No information provided
No information provided
No information provided
No information provided
No information provided
No information provided
Other author: Chulalongkorn University. Faculty of Medicine
Issue Date: Dec-2018
Publisher: NLM (Medline)
Citation: Asian Pacific Journal of Allergy and Immunology. Vol.36, Issue 4 (Dec, 2018), p. 238-243
Abstract: Background: To evaluate long-term effectiveness of omalizumab in ‘real-life’ setting of Thai asthmatic patients. Methods: We conducted multi-center, observational study in severe asthma patients who received omalizumab in Thailand. Outcomes were asthma exacerbation (hospitalization and ER visit), asthma control test (ACT), and daily ICS dose. Data were evaluated at baseline, 16 Week, and 52 Week. Results: A total of 78 patients received omalizumab treatment (average duration 16.9 months with range 16 weeks-2 years). The mean annualized rate of exacerbations was reduced from baseline (3.79) at Week 16 (3.54) and Week 52 (1.16), (p<0.05), respectively. The mean hospitalization rate was reduced from 0.49 in previous year to 0.15 at Week 16 and 0.19 at Week 52. A reduction in ER visit rates was observed at Week 16 (0.15) and Week 52 (0.97) respectively from baseline (1.44) (p<0.05). The ACT score increased from 15.4 at baseline to 20.6 at Week 16 (p<0.001) and increased to 21.5 at Week 52 (p<0.001). The number of patients with controlled asthma (ACT≥20) increased from 16 of 51 at baseline to 32 of 45 at Week 16 and 25 of 32 at week 52, respectively. The median daily dose of ICS equivalent to fluticasone was reduced from baseline 680 mcg to 500 mcg at Week 52. In all, 22 patients discontinued omalizumab after 1 year. Six patients who discontinued omalizumab were restarted due to relapse of symptoms. Conclusions: These data confirms the effectiveness of one-year duration of omalizumab treatment in Thai severe asthmatic patients. Furthermore, 27% of patients who discontinued treatment required restarting due to relapse of symptoms.
URI: http://cuir.car.chula.ac.th/handle/123456789/61734
URI: http://doi.org/10.12932/AP0872
ISSN: 0125-877x
2228-8694
metadata.dc.identifier.DOI: 10.12932/AP0872
Type: Article
Appears in Collections:Chula Scholars - 2018

Files in This Item:
File Description SizeFormat 
html_submission_64679.htmlLink to Fulltext2.66 kBHTMLView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.